|
|
 |
|
Viewing report
|
|
|
|
Specialty Pharmaceutical Industry - 2011 Yearbook
GBI Research, May 2011, Pages: 168
Specialty Pharmaceutical Industry - 2011 Yearbook
Summary
GBI Research's 'Specialty Pharmaceutical Industry - 2011 Yearbook” essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.
Scope
The report covers -
- Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
- Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
- Data and analysis on the specialty pharmaceutical market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
|
|
|
|
